(Q84403500)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Lawrence Steinman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

2358-2360

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Interferon-gamma confers resistance to experimental allergic encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

A rush to judgment on Th17

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

T-bet is essential for encephalitogenicity of both Th1 and Th17 cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

A molecular trio in relapse and remission in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Elevated osteopontin levels in active relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Plasma osteopontin levels in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939814

7 January 2021

Identifiers

DOI

10.1002/EJI.200939814

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19681057%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference